Stocks and Investing Stocks and Investing
Mon, March 21, 2022
Sun, March 20, 2022
Fri, March 18, 2022
Thu, March 17, 2022
Wed, March 16, 2022
Tue, March 15, 2022

Gregory Renza Maintained (SPRB) at Buy with Decreased Target to $9 on, Mar 15th, 2022


Published on 2024-10-27 20:05:38 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Maintained "Spruce Biosciences, Inc." (SPRB) at Buy with Decreased Target from $13 to $9 on, Mar 15th, 2022.

Gregory has made no other calls on SPRB in the last 4 months.



There are 6 other peers that have a rating on SPRB. Out of the 6 peers that are also analyzing SPRB, 2 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Ritu Baral of "Cowen & Co." Downgraded from Buy to Hold on, Tuesday, November 23rd, 2021
  • Joseph Schwartz of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $5 on, Tuesday, November 16th, 2021


These are the ratings of the 4 analyists that currently disagree with Gregory


  • Aydin Huseynov of "Ladenburg Thalmann" Initiated at Strong Buy and Held Target at $6 on, Tuesday, March 8th, 2022
  • Hartaj Singh of "Oppenheimer" Initiated at Buy and Held Target at $15 on, Friday, December 17th, 2021
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $6 on, Tuesday, November 16th, 2021
  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, November 16th, 2021